RAD51 and Breast Cancer Susceptibility: No Evidence for Rare Variant Association in the Breast Cancer Family Registry Study

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Le Calvez Kelm, Florence ^a   Oliver, Javier ^a   Damiola, Francesca ^a   Forey, Nathalie ^a   Robinot, Nivonirina ^a   Durand, Geoffroy ^a   Voegele, Catherine ^a   Vallée, Maxime P ^a   Byrnes, Graham ^a   Breast Cancer Family Registry, ^b,c,d,e   Hopper, John L ^b   Southey, Melissa C ^b   Andrulis, Irene L ^c   John, Esther M ^d,e   Tavtigian, Sean V ^f   Lesueur, Fabienne ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MOUNT SINAI HOSPITAL   (Canada)

^d CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; RAD51 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; XRCC2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; RAD51 GENE; RECOMBINATION REPAIR; RISK ASSESSMENT; RNA SPLICING; SEQUENCE ANALYSIS; SUBSTITUTION REACTION; TUMOR GENE;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; RAD51 RECOMBINASE; REGISTRIES;

EID: 84871644687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052374     Document Type: Article

References (57)

1. Khanna KK, Jackson SP, (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695.
3. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689.
4. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, et al. (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13: 123-125.
5. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
6. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, et al. (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38: 873-875.
7. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, et al. (2009) Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 85: 427-446.
8. Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, et al. (2011) Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 13: R73.
9. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, et al. (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38: 1239-1241.
10. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55-59.
11. Le Calvez-Kelm F, Lesueur F, Damiola F, Vallee M, Voegele C, et al. (2011) Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res 13: R6.
12. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39: 165-167.
13. Erkko H, Dowty JG, Nikkila J, Syrjakoski K, Mannermaa A, et al. (2008) Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 14: 4667-4671.
14. Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, et al. (2010) A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 12: R109.
15. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, et al. (2012) Rare Mutations in XRCC2 Increase the Risk of Breast Cancer. Am J Hum Genet 90: 734-739.
16. West SC, (2003) Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 4: 435-445.
17. Sturzbecher HW, Donzelmann B, Henning W, Knippschild U, Buchhop S, (1996) p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J 15: 1992-2002.
18. Scully R, Chen J, Plug A, Xiao Y, Weaver D, et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-275.
19. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL, (1997) RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272: 31941-31944.
20. Dray E, Etchin J, Wiese C, Saro D, Williams GJ, et al. (2010) Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol 17: 1255-1259.
21. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, et al. (2000) Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88: 907-913.
22. Yoshikawa K, Ogawa T, Baer R, Hemmi H, Honda K, et al. (2000) Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 88: 28-36.
23. Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, et al. (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A 98: 3232-3236.
24. Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, et al. (2004) A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 90: 2002-2005.
25. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, et al. (2007) RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81: 1186-1200.
26. Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, et al. (2011) RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 125: 827-835.
27. Sun H, Bai J, Chen F, Jin Y, Yu Y, et al. (2011) RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects. Breast Cancer Res Treat 125: 157-161.
28. Wang Z, Dong H, Fu Y, Ding H, (2010) RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects. Breast Cancer Res Treat 124: 765-769.
29. Yu KD, Yang C, Fan L, Chen AX, Shao ZM, (2011) RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. Breast Cancer Res Treat 126: 365-371.
30. Yu KD, Li B, Zhou Y, Shao ZM (2011) Is RAD51 135G C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion. Breast Cancer Res Treat 128: 297-299; author reply 300.
31. He XF, Su J, Zhang Y, Ding DP, Wang W, et al. (2011) Need for clarification of data in the recent meta-analysis about RAD51 135G>C polymorphism and breast cancer risk. Breast Cancer Res Treat 129: 649-651; author reply 652-643.
32. Kato M, Yano K, Matsuo F, Saito H, Katagiri T, et al. (2000) Identification of Rad51 alteration in patients with bilateral breast cancer. J Hum Genet 45: 133-137.
33. Rapakko K, Heikkinen K, Karppinen SM, Winqvist R, (2006) Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families. Cancer Lett 236: 142-147.
34. Lose F, Lovelock P, Chenevix-Trench G, Mann GJ, Pupo GM, et al. (2006) Variation in the RAD51 gene and familial breast cancer. Breast Cancer Res 8: R26.
35. Ishida T, Takizawa Y, Sakane I, Kurumizaka H, (2007) Altered DNA binding by the human Rad51-R150Q mutant found in breast cancer patients. Biol Pharm Bull 30: 1374-1378.
36. Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB, (2008) In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 29: 1327-1336.
37. Reese MG, Eeckman FH, Kulp D, Haussler D, (1997) Improved splice site detection in Genie. J Comput Biol 4: 311-323.
38. Yeo G, Burge CB, (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11: 377-394.
39. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42: 410-414.
40. Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, et al. (2010) RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res 12: 404.
41. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, et al. (2010) Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 124: 857-861.
42. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, et al. (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43: 879-882.
43. Lim DS, Hasty P, (1996) A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 16: 7133-7143.
44. Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, et al. (1996) Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A 93: 6236-6240.
45. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, et al. (1998) The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 95: 5287-5292.
46. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, et al. (2002) Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420: 287-293.
47. Park JY, Yoo HW, Kim BR, Park R, Choi SY, et al. (2008) Identification of a novel human Rad51 variant that promotes DNA strand exchange. Nucleic Acids Res 36: 3226-3234.
48. Shin DS, Pellegrini L, Daniels DS, Yelent B, Craig L, et al. (2003) Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2. EMBO J 22: 4566-4576.
49. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, et al. (2004) The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6: R375-389.
50. Voegele C, Tavtigian SV, de Silva D, Cuber S, Thomas A, et al. (2007) A Laboratory Information Management System (LIMS) for a high throughput genetic platform aimed at candidate gene mutation screening. Bioinformatics 23: 2504-2506.
51. Nguyen-Dumont T, Calvez-Kelm FL, Forey N, McKay-Chopin S, Garritano S, et al. (2009) Description and validation of high-throughput simultaneous genotyping and mutation scanning by high-resolution melting curve analysis. Hum Mutat 30: 884-890.
52. Garritano S, Gemignani F, Voegele C, Nguyen-Dumont T, Le Calvez-Kelm F, et al. (2009) Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet 10: 5.
53. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
54. Wallace IM, O'Sullivan O, Higgins DG, Notredame C, (2006) M-Coffee: combining multiple sequence alignment methods with T-Coffee. Nucleic Acids Res 34: 1692-1699.
55. Felsenstein J, (1989) PHYLIP- Phylogeny Inference Package (version 3.2). Cladistics 5: 164-166.
56. Ng PC, Henikoff S, (2002) Accounting for human polymorphisms predicted to affect protein function. Genome Res 12: 436-446.
57. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.